mTOR Inhibition Leads to Src-Mediated EGFR Internalisation and Degradation in Glioma Cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Epidermal Growth Factor receptor (EGFR) is a key regulator of cell proliferation, migration, and survival.
• EGFR alterations are implicated in various cancers, including glioblastoma (GBM), driving uncontrolled cell growth.
• The mammalian target of Rapamycin (mTOR) pathway plays a crucial role in cellular processes and cancer progression.

Purpose of the Study:

• To investigate the effect of mTOR inhibition on EGFR in glioblastoma cells.
• To elucidate the downstream signaling pathways affected by mTOR inhibition in GBM.
• To evaluate the potential of mTOR targeting as a therapeutic strategy for glioblastoma.

Main Methods:

• Utilized glioblastoma cell models to study EGFR regulation.
• Assessed the impact of mTOR inhibition on EGFR localization and degradation.
• Analyzed downstream signaling pathways, including MAPK/ERK and Src kinase activation.

Main Results:

• mTOR inhibition promotes lysosomal degradation of EGFR in GBM cells, independent of autophagy.
• EGFR internalization upon mTOR inhibition requires Src kinase activation.
• mTOR blockade negatively impacts the MAPK/ERK pathway, a critical pro-proliferative signaling cascade.

Conclusions:

• mTOR inhibition effectively targets EGFR degradation in glioblastoma.
• Targeting mTOR alters key proliferative signaling pathways in GBM.
• mTOR inhibition presents a promising therapeutic avenue for glioblastoma management.